See every side of every news story
Get Started
SubscribeLogin
SAG Awards
Olaf Scholz
Pope Francis
German Politics
Donald Trump
Ukraine War
Volodymyr Zelenskyy
Israel-Hamas Conflict
Hamas
Wrestling
Basketball
Elon Musk
Published • loading... • Updated

THT 2025: MODERATO II study demonstrates improved echo markers of diastolic dysfunction through AVIM therapy

Summary by Cardiovascular News
Orchestra BioMed has announced a late-breaking presentation of data on the benefits of atrioventricular interval modulation (AVIM) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (THT) conference (11–13 February, Boston, USA). The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic markers of diastolic dysfunction, an imp…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
Cardiovascular NewsCardiovascular News

THT 2025: MODERATO II study demonstrates improved echo markers of diastolic dysfunction through AVIM therapy

Orchestra BioMed has announced a late-breaking presentation of data on the benefits of atrioventricular interval modulation (AVIM) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (THT) conference (11–13 February, Boston, USA). The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic markers of diastolic dysfunction, an imp…

Read Full Article
Medical Device News MagazineMedical Device News Magazine

Orchestra BioMed Announces Data Demonstrating Favorable Impact Of AVIM Therapy On Diastolic Dysfunction, A Key Driver Of Heart Failure Progression | To Be Presented As Late-Breaking Science At The THT 2025 Conference - Medical Device News Magazine

Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Device News Magazine broke the news in on Wednesday, February 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Boston, Massachusetts

Boston, Massachusetts

News
For You
Search
BlindspotLocal